Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy
- 24 September 2014
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 15 (1) , 121-128
Abstract
(2015). Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy. Expert Review of Anticancer Therapy: Vol. 15, No. 1, pp. 121-128.Keywords
This publication has 19 references indexed in Scilit:
- Improved curve fits to summary survival data: application to economic evaluation of health technologiesBMC Medical Research Methodology, 2011
- Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)Annals of Oncology, 2010
- Targeted therapies in the treatment of advanced/metastatic NSCLCEuropean Journal of Cancer, 2009
- Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiLJournal of Clinical Oncology, 2009
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2008
- The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant TumoursJournal of Thoracic Oncology, 2007
- The IASLC Lung Cancer Staging Project: Validation of the Proposals for Revision of the T, N, and M Descriptors and Consequent Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant TumoursJournal of Thoracic Oncology, 2007
- Practical methods for incorporating summary time-to-event data into meta-analysisTrials, 2007
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyJournal of Clinical Oncology, 2004